

BÜHLMANN launches Home Testing Device for IBD Patients

The IBDoc™ is an easy to use tool for patients to perform the calprotectin stool test without leaving their home.

The test is performed in three easy steps. After the collection of a stool sample with a novel stool extraction device, CALEX®, a measured amount of stool extract is applied onto a calprotectin test cassette and the result is read with the help of a smart phone application. The results are displayed in a traffic light code as well as fully quantitative values. The results are immediately sent via the internet and stored in a web based patient file, accessible to the patient, the supervising clinician, and health care professionals.

“The IBDoc™ can be seen as a revolution in patient management similar to the introduction of home testing for diabetes patients a generation ago”, says Dr. Arne Roseth, Medical Director of BÜHLMANN. “The IBDoc™ empowers the patient in their disease management, and builds a bridge between them and the health care professional.”

Faecal calprotectin is a highly sensitive early inflammation marker to help identify organic inflammations of the digestive system. Numerous clinical studies demonstrate that faecal calprotectin not only helps to monitor the disease activity of Inflammatory Bowel Disease (IBD) patients, but that it also serves as a prognostic marker to detect potential flares ahead of time.

IBD describes chronic, life-long organic diseases also known as Crohn’s Disease or Ulcerative Colitis. About 5 Million people around the world suffer from the disease. “With IBDoc™, BÜHLMANN launches an easy to use device at the peak of technological innovation”, says Dr. Chris Moore, Chief Product Officer of BÜHLMANN Laboratories, “but what makes us particularly proud is to offer to the often young and active patients a unique tool to help monitor and control their disease.”

BÜHLMANN Laboratories today is the leading “calprotectin company”, offering the broadest menu of calprotectin assays for fully automated laboratory application or a unique quantitative rapid test “Quantum Blue®”. IBDoc™ is planned to be released for patients by the end of 2014.

The company was founded in 1976 (www.buhlmannlabs.ch). The BÜHLMANN Group today includes affiliates in France, Italy, Austria, Brazil and direct sales to Germany. BÜHLMANN products are available through a broad network of qualified distributors globally.

Basel, 19 February 2014

For more information, contact: Dr. Chris Moore, Chief Product Officer
email: cm@buhlmannlabs.ch; Cell: +41 79 752 34 59;